Home › Trials › NCT05564377

Targeted therapy for advanced solid tumors based on genetic testing

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Phase 2 Interventional National Cancer Institute (NCI) · NCT05564377

This study is testing whether matching patients with advanced solid tumors to specific treatments based on their genetic makeup can improve their outcomes when standard options have failed.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment2900 (estimated)
SexAll
SponsorNational Cancer Institute (NCI) NIH
Drugs / interventionspanitumumab, selumetinib, binimetinib, nilotinib, neratinib
Locations479 sites (Birmingham, Alabama and 478 other locations)
Trial IDNCT05564377 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to match patients with locally advanced or advanced solid tumors to targeted therapies based on genetic testing results. Patients who have progressed on standard treatments or have no effective standard options will undergo genetic testing to identify specific mutations in their tumors. The trial will register and allocate patients to various treatment combinations that may be more effective for their unique genetic profiles. Additionally, the study will evaluate treatment outcomes and the accuracy of genetic characterizations from biopsy samples.

Who should consider this trial

Good fit: Ideal candidates include adults with locally advanced or advanced solid tumors who have not responded to standard therapies or have no standard treatment options available.

Not a fit: Patients with early-stage tumors or those who have not yet undergone standard systemic therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this approach could lead to more effective, personalized cancer treatments for patients with advanced solid tumors.

How similar studies have performed: Other studies utilizing genetic testing to guide targeted therapies have shown promising results, indicating potential success for this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patient must have measurable disease
* Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status between 0-2 OR patient must have Lansky performance status of \>= 50% or Karnofsky performance status of \>= 50%
* Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider
* All patients must have sequencing results available from a National Cancer Institute (NCI) credentialed Designated Laboratory (DL)
* Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria:

  * Patients must have progressed on at least one line of standard systemic therapy OR
  * Patients whose disease has no standard treatment that has been shown to prolong overall survival
* Patient must meet one of the following requirements:

  * Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial OR
  * Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:

    * Tissue must have been collected within 12 months prior to registration to the EAY191 Registration Trial
    * Patient must not have had a Response Evaluation Criteria in Solid Tumors (RECIST) response (complete response \[CR\] or partial response \[PR\]) to any intervening therapy after collection of the tissue
    * Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available OR
  * Patients under 18 years old must confirm availability of an archival tumor tissue specimen for submission for research if patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:

    * Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available
  * NOTE: See specific ComboMATCH Treatment Trial protocol for tissue collection and management instructions. Performance of the mandatory research biopsy or submission of pre-trial formalin-fixed paraffin-embedded (FFPE) and collection and submission of the blood specimens for the integrated studies will be performed under the consent authority of the specific treatment trial protocol to which the patient is registered. No procedures to collect specimens for research only are to be performed for patients registered to the EAY191 Registration Trial only
* NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If patient is found to not be eligible for the assigned ComboMATCH Treatment Trial, indication of ineligibility will trigger re-evaluation and potential assignment to another Treatment Trial

Where this trial is running

Birmingham, Alabama and 478 other locations

+429 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Malignant Solid NeoplasmMalignant Female Reproductive System NeoplasmMetastatic HER2-Negative Breast CarcinomaMetastatic Malignant Solid NeoplasmRecurrent Endometrial Carcinoma
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.